FDA aims to decide on ISTA's once-daily eye drug by mid-October

03/8/2010 | Google

The FDA set Oct. 16 as its approval deadline for ISTA Pharmaceuticals' XiDay, a once-daily formulation of eye drug Xibrom. Both drugs are indicated for eye inflammation after cataract surgery.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Finance Manager - ENT
Jacksonville, FL
President/Chief Executive Officer
Winston-Salem, NC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Director, Payer Marketing
Avalere Health
Washington, DC